TAK-226-3001: A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions

A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions
Principal Investigator
Sdrimas, Konstantinos
Phase
III
Age Group
Adult
Applicable Disease Sites
Multiple Myeloma
Participating Institutions
Mary Babb Randolph Cancer Center
Contacts
Kathryn Oliverio, LPN
Research Specialist
Phone: +1 304-293-7374
Email:

View on ClinicalTrials.gov

Quick Search

Use the full search for additional searching options.